Hims & Hers Health (NYSE:HIMS) Stock Falls 7.3% – Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) traded down 7.3% during mid-day trading on Tuesday. The stock traded as low as $17.25 and last traded at $17.2030. Approximately 5,529,756 shares traded hands during trading, a decline of 75% from the average session volume of 22,187,676 shares. The stock had previously closed at $18.56.

Analysts Set New Price Targets

HIMS has been the topic of several analyst reports. JPMorgan Chase & Co. started coverage on Hims & Hers Health in a report on Friday, September 11th. They issued a “neutral” rating and a $32.00 price objective on the stock. Truist Financial increased their target price on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a report on Monday, August 24th. Bank of America raised their price target on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Morgan Stanley decreased their price target on Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 10th. Finally, Deutsche Bank boosted their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $31.53.

Read Our Latest Research Report on Hims & Hers Health

Hims & Hers Health Price Performance

The company has a current ratio of 0.92, a quick ratio of 0.87 and a debt-to-equity ratio of 3.85. The company has a market capitalization of $4.12 billion, a PE ratio of -21.25 and a beta of 2.53. The stock’s 50-day moving average is $27.43 and its two-hundred day moving average is $26.65.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03). The company had revenue of $890.37 million for the quarter, compared to analysts’ expectations of $893.13 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The firm’s revenue for the quarter was up 48.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.06 earnings per share. On average, equities analysts predict that Hims & Hers Health, Inc. will post -0.21 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 25,111 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the sale, the insider owned 313,964 shares of the company’s stock, valued at approximately $8,649,708.20. This trade represents a 7.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the completion of the transaction, the chief operating officer owned 456,660 shares in the company, valued at $12,964,577.40. This trade represents a 2.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 107,744 shares of company stock worth $3,098,017. Corporate insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Institutional investors have recently made changes to their positions in the business. Blue Jean Financial LLC purchased a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $3,159,000. B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $2,992,000. FirstWave Capital Management LLC raised its stake in shares of Hims & Hers Health by 30.6% during the 2nd quarter. FirstWave Capital Management LLC now owns 339,978 shares of the company’s stock valued at $11,787,000 after buying an additional 79,731 shares during the last quarter. Concurrent Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 109.8% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 35,272 shares of the company’s stock valued at $1,223,000 after buying an additional 18,459 shares during the period. Finally, Prosperitas Financial LLC acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $2,649,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

See Also

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.